Protean Presents on the Importance of Precision Medicine in Uncovering a Patient's True Diagnosis at AMP 22

Protean presents a case study that highlights the ability to catch a liver carcinoma misdiagnosis using pathology review, comprehensive in-house molecular testing, and virtual molecular tumor boards.

Anthony MaglioccoOctober 20, 2022

Protean BioDiagnostics, Inc. Partners with Qualisure Diagnostics, Inc.

Protean BioDiagnostics Enhances Thyroid Cancer Care for Patients with the addition of the Latest Leading Test to its Protean MAPS™ Diagnostic Menu.

Anthony MaglioccoSeptember 6, 2022

Protean Will Provide Results From a Study of Endometrial Cancer in African Americans and Caucasian Americans at ASCO 2022 in Chicago

African American patients have a worse outcome, regardless of the molecular subtype of cancer. In White patients molecular subtypes were associated with better outcomes.

Anthony MaglioccoMay 31, 2022

The Impact of Molecular Features on Outcome in Black Women With Type 1 Endometrial Cancer

Among women with endometrial cancer (EC), African American or Black (AAoB) population share a disproportionate burden of cancer deaths. Here, we aim to focus on molecular differences between racial groups, specifically in Type 1 EC (T1EC).

Anthony MaglioccoMay 17, 2022

Using Optical Genome Mapping and NGS to Understand Epitheliod Sarcoma in a Pediatric Patient

Combining traditional next generation sequencing with optical genome mapping presents a robust picture of the precise genomic alterations.

Anthony MaglioccoMay 5, 2022

Embryonal Rhabdomyosarcoma in a Pediatric Patient: Therapeutic Target Identification

A rare pediatric soft tissue tumor was analyzed to determine therapeutic targets. By combining multiple types of analysis, it was uncovered that this patient was eligible for a novel clinical trial containing MEK and PD-L1 checkpoint inhibitors.

Anthony MaglioccoMay 5, 2022